Here, we have used the ERK inhibitor SCH772984 as a tool to investigate the molecular determinants of resistance to ERK inhibition in BRAF-V600E melanomas and assessed the potential therapeutic value of co-targeting ERK and the Notch pathway. Here, BRAF is linked to melanoma.